PMID- 28187863
OWN - NLM
STAT- MEDLINE
DCOM- 20180220
LR  - 20220321
IS  - 1879-114X (Electronic)
IS  - 0149-2918 (Linking)
VI  - 39
IP  - 8S2
DP  - 2017 Aug
TI  - A Review of the Clinical Efficacy and Safety of Insulin Degludec and Glargine 300 
      U/mL in the Treatment of Diabetes Mellitus.
PG  - S12-S33
LID - S0149-2918(17)30040-1 [pii]
LID - 10.1016/j.clinthera.2017.01.007 [doi]
AB  - PURPOSE: The treatment of type 1 diabetes mellitus (T1DM) and type 2 diabetes 
      mellitus (T2DM) using insulin is not ideal at this time. Despite advances made 
      with basal insulin analogues, many individuals achieve less than optimal glycemic 
      control or are at risk for hypoglycemia. Currently available basal insulin 
      analogues do not deliver steady, peakless, continuous insulin for >24 hours and 
      are associated with adverse events, including hypoglycemia. The objective of this 
      paper was to review the clinical efficacy and safety of upcoming long-acting 
      insulin analogues such as insulin degludec and insulin glargine 300 U/mL 
      (Gla-300). METHODS: A comprehensive literature search of PubMed and Google 
      Scholar was conducted from 1966 to 2015. The search included randomized 
      controlled trials that specifically assessed the efficacy and safety of insulin 
      degludec and Gla-300 in patients with T1DM and T2DM. FINDINGS: The efficacy of 
      insulin degludec and Gla-300 in achieving glycemic control has been reported in 
      clinical trials in adults with T1DM and T2DM. Not only did a large number of 
      patients succeed in meeting glycosylated hemoglobin targets, but they also 
      experienced reductions in hypoglycemic events. These 2 therapies are associated 
      with a reduced risk of nocturnal hypoglycemia and are generally well tolerated. 
      IMPLICATIONS: The long-acting insulin analogues insulin degludec and Gla-300 are 
      promising therapies in the treatment of T1DM and T2DM. Their improved insulin 
      delivery for >24 hours offers glycemic control with a good safety profile.
CI  - Copyright (c) 2017 Elsevier HS Journals, Inc. All rights reserved.
FAU - Woo, Vincent C
AU  - Woo VC
AD  - Section of Endocrinology and Metabolism, Health Sciences Centre, University of 
      Manitoba, Winnipeg, Manitoba, Canada. Electronic address: 
      vincent.woo@umanitoba.ca.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20170207
PL  - United States
TA  - Clin Ther
JT  - Clinical therapeutics
JID - 7706726
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Insulin, Long-Acting)
SB  - IM
MH  - Diabetes Mellitus, Type 1/*drug therapy
MH  - Diabetes Mellitus, Type 2/*drug therapy
MH  - Humans
MH  - Hypoglycemic Agents/adverse effects/*therapeutic use
MH  - Insulin, Long-Acting/adverse effects/*therapeutic use
MH  - Treatment Outcome
OTO - NOTNLM
OT  - glargine
OT  - insulin degludec
OT  - type 1 diabetes mellitus
OT  - type 2 diabetes mellitus
EDAT- 2017/02/12 06:00
MHDA- 2018/02/21 06:00
CRDT- 2017/02/12 06:00
PHST- 2016/10/18 00:00 [received]
PHST- 2016/12/30 00:00 [revised]
PHST- 2017/01/04 00:00 [accepted]
PHST- 2017/02/12 06:00 [pubmed]
PHST- 2018/02/21 06:00 [medline]
PHST- 2017/02/12 06:00 [entrez]
AID - S0149-2918(17)30040-1 [pii]
AID - 10.1016/j.clinthera.2017.01.007 [doi]
PST - ppublish
SO  - Clin Ther. 2017 Aug;39(8S2):S12-S33. doi: 10.1016/j.clinthera.2017.01.007. Epub 
      2017 Feb 7.